Dr Reddys Laboratories (RDY) Liabilities and Shareholders Equity (2009 - 2026)
Dr Reddys Laboratories (RDY) posted quarterly Liabilities and Shareholders Equity of $6.2 billion for Q1 2026, up 6.98% year-over-year from $5.8 billion in Q1 2025, and up 6.98% quarter-over-quarter from $5.8 billion in Q1 2025.
Dr Reddys Laboratories (RDY) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $6.2 billion for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 6.98% year-over-year to $6.2 billion; the TTM figure through Mar 2026 stood at $16.6 billion (up 15.76% YoY), while the FY2026 annual figure was $6.2 billion, up 6.98% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $6.2 billion, up from $5.8 billion in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $6.2 billion in Q1 2026, with the low at $3.9 billion in Q1 2022.
- The 5-year median for Liabilities and Shareholders Equity is $4.6 billion (2024), against an average of $4.9 billion.
- The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity climbed 1.45% in 2023, then advanced 24.13% in 2025.
- Dr Reddys Laboratories' Liabilities and Shareholders Equity stood at $3.9 billion in 2022, then gained by 1.45% to $3.9 billion in 2023, then advanced by 18.74% to $4.6 billion in 2024, then rose by 24.13% to $5.8 billion in 2025, then grew by 6.98% to $6.2 billion in 2026.
- Business Quant data shows RDY's Liabilities and Shareholders Equity at $6.2 billion in Q1 2026, $5.8 billion in Q1 2025, and $4.6 billion in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | 6.18 Bn |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 4.39 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.18 Bn |
| Mar 31, 2025 | 5.77 Bn |
| Mar 31, 2024 | 4.65 Bn |
| Mar 31, 2023 | 3.92 Bn |
| Mar 31, 2022 | 3.86 Bn |
| Mar 31, 2021 | 3.63 Bn |
| Mar 31, 2020 | 3.08 Bn |
| Mar 31, 2019 | 3.26 Bn |
| Mar 31, 2018 | 3.47 Bn |
| Dec 31, 2009 | 1.57 Bn |
| Sep 30, 2009 | 1.72 Bn |
| Jun 30, 2009 | 1.76 Bn |